A tiny glimpse at very early data has more than tripled Macrogenics’ market cap. The pressure is now on to confirm these signals.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study.
Demonstrating an overall survival benefit remains crucial for Macrogenics’ anti-Her2 antibody margetuximab, for regulatory approval and any partnering deals alike.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…